Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment

Second-line treatments are standard care for advanced hepatocellular carcinoma (HCC) patients with preserved liver function who are intolerant of or progress on first-line therapy. However, determinants of treatment benefit and post-treatment survival (PTS) remain unknown. HCC patients previously tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Personeni, Nicola, Pressiani, Tiziana, Zanuso, Valentina, Casadei-Gardini, Andrea, D’Alessio, Antonio, Valgiusti, Martina, Dadduzio, Vincenzo, Bergamo, Francesca, Soldà, Caterina, Rizzato, Mario Domenico, Giordano, Laura, Santoro, Armando, Rimassa, Lorenza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604940/
https://www.ncbi.nlm.nih.gov/pubmed/36294865
http://dx.doi.org/10.3390/jpm12101726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604940/
https://www.ncbi.nlm.nih.gov/pubmed/36294865
http://dx.doi.org/10.3390/jpm12101726

Ejemplares similares